New Delhi, March 13 -- Sun Pharmaceutical Industries Ltd's latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business-an area of focus. Checkpoint is an immunotherapy and targeted oncology company. The move will help Sun Pharma expand its portfolio of products for skin cancer within the speciality business.

The key product owned by Checkpoint is Unloxcyt, a drug used to treat cutaneous squamous cell carcinoma (cSCC), a type of skin cancer, approved by the US FDA in December but still to be commercialised. The product can be expected to form the basis of products for other types of cancers as well.

"Unloxcyt (Cosibelimab; skin cancer) will complement its existing speciality products like Odomzo ...